Incidence and Predictors of Early Death in Patients Undergoing Percutaneous Left Atrial Appendage Closure.


Journal

JACC. Clinical electrophysiology
ISSN: 2405-5018
Titre abrégé: JACC Clin Electrophysiol
Pays: United States
ID NLM: 101656995

Informations de publication

Date de publication:
Sep 2022
Historique:
received: 21 03 2022
revised: 25 05 2022
accepted: 09 06 2022
entrez: 22 9 2022
pubmed: 23 9 2022
medline: 28 9 2022
Statut: ppublish

Résumé

Left atrial appendage closure (LAAC) aims to prevent ischemic events in patients with atrial fibrillation. As a preventive procedure, early death after LAAC could render the procedure futile. The authors sought to evaluate the incidence and factors associated with early death in LAAC recipients. This was a multicenter study including consecutive patients undergoing LAAC in a 10-year period (2009-2019). Death was considered early when occurring in the first year after LAAC. A total of 807 patients (mean age 76 ± 8 years, mean CHA In this multicenter international registry, close to 1 in 6 patients died within the first year of LAAC. Older age, low body mass index, impaired estimated glomerular filtration rate, prior diabetes, and prior heart failure are independently associated with an increased risk. The risk of early death appeared to be prohibitive (∼50%) in the presence of >3 of these risk factors.

Sections du résumé

BACKGROUND
Left atrial appendage closure (LAAC) aims to prevent ischemic events in patients with atrial fibrillation. As a preventive procedure, early death after LAAC could render the procedure futile.
OBJECTIVES
The authors sought to evaluate the incidence and factors associated with early death in LAAC recipients.
METHODS
This was a multicenter study including consecutive patients undergoing LAAC in a 10-year period (2009-2019). Death was considered early when occurring in the first year after LAAC.
RESULTS
A total of 807 patients (mean age 76 ± 8 years, mean CHA
CONCLUSIONS
In this multicenter international registry, close to 1 in 6 patients died within the first year of LAAC. Older age, low body mass index, impaired estimated glomerular filtration rate, prior diabetes, and prior heart failure are independently associated with an increased risk. The risk of early death appeared to be prohibitive (∼50%) in the presence of >3 of these risk factors.

Identifiants

pubmed: 36137713
pii: S2405-500X(22)00555-2
doi: 10.1016/j.jacep.2022.06.012
pii:
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1093-1102

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2022 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Funding Support and Author Disclosures Dr Mesnier is supported by a research grant from the Fédération Française de Cardiologie. Dr Rodés-Cabau holds the Research Chair “Fondation Famille Jacques Larivière” for the Development of Structural Heart Disease Interventions; and has received institutional research grants from Boston Scientific. Dr Cruz-González is a proctor for Boston Scientific, Abbott, and Lifetech. Dr Nombela-Franco is a proctor for Abbott. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Auteurs

Jules Mesnier (J)

Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada.

Ignacio Cruz-González (I)

University Hospital Salamanca, Salamanca, Spain.

Dabit Arzamendi (D)

Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

Xavier Freixa (X)

Institut Clínic Cardiovascular, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain.

Luis Nombela-Franco (L)

Cardiovascular Institute, Hospital Clínico San Carlos, Madrid, Spain.

Vicente Peral (V)

Department of Cardiology, Hospital Universitari Son Espases (HUSE), Institut d'Investigació Sanitària Illes Balears (IdISBa), Palma, Balearic Islands, Spain.

Berenice Caneiro-Queija (B)

University Hospital Alvaro Cunqueiro, Vigo, Spain.

Antonio Mangieri (A)

GVM Care and Research, Maria Cecilia Hospital, Cotignola, Italy.

Blanca Trejo-Velasco (B)

University Hospital Salamanca, Salamanca, Spain.

Lluis Asmarats (L)

Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

Ander Regueiro (A)

Institut Clínic Cardiovascular, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain.

Angela McInerney (A)

Cardiovascular Institute, Hospital Clínico San Carlos, Madrid, Spain.

Caterina Mas-Lladó (C)

Department of Cardiology, Hospital Universitari Son Espases (HUSE), Institut d'Investigació Sanitària Illes Balears (IdISBa), Palma, Balearic Islands, Spain.

Rodrigo Estevez-Loureiro (R)

University Hospital Alvaro Cunqueiro, Vigo, Spain.

Alessandra Laricchia (A)

GVM Care and Research, Maria Cecilia Hospital, Cotignola, Italy.

Gilles O'Hara (G)

Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada.

Josep Rodés-Cabau (J)

Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada; Institut Clínic Cardiovascular, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain. Electronic address: josep.rodes@criucpq.ulaval.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH